Daily Hong Kong stock market news express (December 9th, Friday)
Important news
1. China Association of Automobile Manufacturers (CAAM): The retail sales of passenger vehicles in November reached 1.649 million units, a year-on-year decrease of 9.2%; the wholesale sales of new energy passenger vehicles reached 0.728 million units, a year-on-year increase of 70.2% and a month-on-month increase of 7.9%.
Individual stock news
1. Guangzhou Automobile Group Co., Ltd. (02238.HK): The automobile sales in November were 190,305 units, a year-on-year decrease of 15.09%; the sales of new energy vehicles were 33,737 units, a year-on-year increase of 89.99%.
2. Great Wall Motor (02333.HK): Total sales volume in November was 87,560 units, a decrease of 28.53% year-on-year; sales of electric vehicles were 12,863 units, a decrease of 23% year-on-year.
3. China Traditional Chinese Medicine (00570.HK): According to China National Medical Products Administration, China National Medical Group has preliminarily studied and will not privatize the company.
4. Remegen (09995.HK) announced that their innovative antibody-drug conjugate RC118 has received two orphan drug designations from the U.S. Food and Drug Administration for the treatment of gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer.
5. Hopson Development Holdings (00754.HK): The total sales amount of contracts in the first 11 months was about 28.113 billion yuan, a decrease of about 27.73% year-on-year; of which, the sales amount of property contracts was about 26.121 billion yuan, a decrease of about 29.56% year-on-year.
6. Yuexiu Property (00123.HK): The contract sales amount in November was about 11.828 billion yuan, a decrease of about 11% year-on-year; the cumulative contract sales amount in the first 11 months was about 102.94 billion yuan, an increase of about 8% year-on-year, achieving 83% of the 2022 contract sales target of 123.5 billion yuan.
7. Saisheng Pharmaceutical (06600.HK): The biological product license application for Dabuzer® (Naxitumumab) has been approved by the National Medical Products Administration, allowing its use for treating relapsed or refractory high-risk neuroblastoma patients in China.
8. Jiumaojiu (09922.HK): CEO and controlling shareholder Guan Yihong sold a total of 48 million shares of the company on December 8, accounting for approximately 3.30% of the total issued share capital, for a total price of 0.888 billion Hong Kong dollars.
9. Air China Limited (00753.HK) has received approval from the China Securities Regulatory Commission to non-publicly issue up to 4.357 billion new shares.
10. China Suntien (00956.HK): In November, the power generation completed on a consolidated basis was 1.2395 million megawatt-hours, a decrease of 15.43% year-on-year; the cumulative power generation completed in the first 11 months was 12.4935 million megawatt-hours, an increase of 3.83% year-on-year.
11. Powerlong Real Estate (01238.HK): The contract sales in November amounted to approximately 3.245 billion yuan; the total contract sales in the first 11 months amounted to approximately 37.932 billion yuan, a decrease of 59.27% year-on-year.
12. Sunac China (01918.HK) 2021 annual report shows that its annual revenue in 2021 was approximately 198.39 billion yuan, a decrease of approximately 14.0% compared to last year; the net loss attributable to shareholders was approximately 38.26 billion yuan, a decrease of approximately 207.4% compared to last year.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
